Jon Hu

Shared my thoughts on 2024's pharma trends with @PharmaVoice's @MeaganParrish. Despite the challenges ahead there are big opportunities too. More on how March-In rights might impact biotech, and other trends from industry leaders here: bit.ly/3ScB21H

@PepperBio is featured in @TechCrunch’s Pitch Deck Teardown! @Haje's insights on our $6.5M seed pitch stress the value of personal connections in biotech – a reminder to tailor messages effectively when merging science and storytelling bit.ly/3tGM31X

Join us in giving a warm welcome to Dr. Martin Alexander Gershon, @endeavorfunds, who is starting his role as our senior strategic advisor. Read about his role with @pepper_bio here: bit.ly/48lFH7j #transomics  #drugdiscovery

How are startups already using AI to transform the way we approach drug discovery? More on this in @WSJ via my conversation with @BrianPGormley and @SamanthaDStrass. wsj.com/articles/start…

My op-ed in @statnews explores how patient advocacy groups influence FDA approvals for drugs that don’t have robust clinical data proving impact. Here’s why that's a problem & how I think we can positively redirect patient advocacy for better outcomes: bit.ly/3GPjxhE

Investors like @Merck + @NFX helped us further understand the need for solutions like Pepper Bio in the pharma space. Samantha & I spoke with @RebeccaTorrenc5 from @BusinessInsider, who covers the pitch deck that led to our seed funding. Check it out here: bit.ly/3thxp0L

With our $6.5M seed funding, @PepperBio isn't just advancing drug development; we're accelerating discoveries to put an end to untreatable diseases. Learn more about the funding of our transomics analysis platform via @abracarioca’s latest in @TechCrunch. bit.ly/3RpvnVP

Transomics has the ability to find ways to circumvent drug resistance in diseases like non-small cell lung cancer. Read about our research findings as @Pepper_Bio heads to @AACR in Boston: pepper.bio/overcoming-egf… @theNCI @EORTC

@JAMANetworkOpen @VPrasadMDMPH @US_FDA @DavidBenjaminMD @mlythoe It'd be interesting to look at cost data. Did 1st-line displacing therapies and 1L alternatives actually create any pricing pressure? If so, how do we realistically increase 1L drugs given logistical challenges in patient recruitment?

Between 2016 and 2021, there were 207 cancer drug approvals by @US_FDA. Of these approvals, 28 therapies (14%) displaced the standard of care while 86 therapies (42%) were in the second-, third- or later-line setting @DavidBenjaminMD @mlythoe @VPrasadMDMPH ja.ma/3i7yxen

As a kid who was in ESL when I first immigrated to the USA, it is a childhood dream come true, to contribute to Forbes. The Root Cause Of Pharma’s Drug Development Problem via @forbes forbes.com/sites/forbeste…